Cargando…

Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)

Oxycodone DETERx(®) (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended‐release, microsphere‐in‐capsule, abuse‐deterrent formulation designed to retain its extended‐release properties after tampering (eg, chewing/crushing). This randomized, double‐blind, placebo‐controlled, triple‐d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kopecky, Ernest A., Fleming, Alison B., Levy‐Cooperman, Naama, O'Connor, Melinda, M. Sellers, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Drug Abuse Deterrence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363337/ https://www.ncbi.nlm.nih.gov/pubmed/27669664 http://dx.doi.org/10.1002/jcph.833

Ejemplares similares

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial
por: Kopecky, Ernest A., et al.
Publicado: (2017)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations
por: Mayock, Stephen P., et al.
Publicado: (2017)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Trends in investigations of abuse or neglect referred by hospital personnel in Ontario
por: Fallon, Barbara, et al.
Publicado: (2019)

Child abuse in children living with special guardians, a service evaluation of child protection medical examinations
por: Garstang, Joanna, et al.
Publicado: (2021)

Reliability of the Sexual Knowledge Picture Instrument: a potential diagnostic instrument for sexual abuse in young children
por: van Ham, Kirsten, et al.
Publicado: (2022)

Reactions of non-abused children aged 3–9 years to the Sexual Knowledge Picture Instrument: an interview-based study
por: van Ham, Kirsten, et al.
Publicado: (2021)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Nonmedical Use of Xtampza(®) ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV(®))
por: Green, Jody L, et al.
Publicado: (2021)

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
por: Olatoke, Oluwadara, et al.
Publicado: (2022)

Introduction to the child abuse imaging special issue
por: Strouse, Peter J., et al.
Publicado: (2021)

Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations”
por: Fleming, Alison B., et al.
Publicado: (2018)

The impact of the consensus statement on abusive head trauma in infants and young children
por: Choudhary, Arabinda K.
Publicado: (2021)

Sibling screening in suspected abusive head trauma: a proposed guideline
por: Mankad, Kshitij, et al.
Publicado: (2021)

Evaluation of the efficacy and impact of a clinical prediction tool to identify maltreatment associated with children’s burns
por: Hollen, Linda, et al.
Publicado: (2021)

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”
por: Gudin, Jeff, et al.
Publicado: (2017)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

A retrospective chart review of opioid represcribing following nonfatal overdose at a Veterans Affairs hospital
por: Boyle, Julia, et al.
Publicado: (2018)

Implementation and results of a symptom-triggered opioid withdrawal protocol at a Veterans Affairs medical center
por: Koch, Jessa, et al.
Publicado: (2018)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

Factors associated with adverse childhood experiences in Scottish children: a prospective cohort study
por: Marryat, Louise, et al.
Publicado: (2019)

Burden of adverse childhood experiences in children attending paediatric clinics in South Western Sydney, Australia: a retrospective audit
por: Wickramasinghe, Yuanee Mary, et al.
Publicado: (2019)

Nicotine Gateway Effects on Adolescent Substance Use
por: Ren, Michelle, et al.
Publicado: (2019)

Characteristics of child welfare investigations reported by healthcare professionals in Ontario: secondary analysis of a regional database
por: Livingston, Eliza, et al.
Publicado: (2021)

Liderazgo en la prevención de uso y abuso de drogas : una experiencia /
Publicado: (2012)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations
por: Crudele, Nancy, et al.
Publicado: (2018)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Geriatric Opioid Harm Reduction: Interprofessional Student Learning Outcomes
por: Zanjani, Faika, et al.
Publicado: (2020)

Reducing Medication Risks in Older Adult Drinkers
por: Zanjani, Faika, et al.
Publicado: (2020)

A qualitative investigation of the role of the family in structuring young people’s alcohol use
por: Jacob, Nina, et al.
Publicado: (2016)

The Medical Management of Consumptives
Publicado: (1912)

Sanatoria in the Light of the Departmental Report
Publicado: (1912)

Cannot write session to /tmp/vufind_sessions/sess_dmmo9q9klfffgq2ln7bbj2kvtn